All Updates

All Updates

icon
Filter
M&A
SOHM announces acquisition of gene editing platform from CGA 369
Human Gene Editing
Sep 25, 2023
This week:
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Funding
Herald raises USD 12 million in Series A funding to enhance AI capabilities
InsurTech: Infrastructure
Oct 16, 2024
Partnerships
ActiveViam partners with MongoDB to enhance real-time data analytics for financial industry
Data Infrastructure & Analytics
Oct 16, 2024
Management news
CapWay shuts down operations
Neobanks
Oct 16, 2024
Funding
LanzaTech secures USD 3 million from US DOE to advance CO2 conversion
Carbon Capture, Utilization & Storage (CCUS)
Oct 16, 2024
Industry news
Denmark to invest USD 2.1 billion in climate transition research
Livestock Biotech
Oct 16, 2024
Industry news
Denmark to invest USD 2.1 billion in climate transition research
Plant-based Meat
Oct 16, 2024
Human Gene Editing

Human Gene Editing

Sep 25, 2023

SOHM announces acquisition of gene editing platform from CGA 369

M&A

  • Pharmaceutical company SOHM has acquired ABBIE, a gene-editing platform, for USD 10 million from cell biotech company CGA 369.

  • The acquisition marks SOHM’s entry into the gene-editing market, which is expected to reach USD 10.8 billion by 2028. ABBIE is currently under development, and it is expected to reach in-human trials by the end of 2025. The acquisition will enable SOHM to generate revenue through licensing and the release of gene-editing kits. Additionally, ABBIE will also help SOHM tap into the global biotechnology kit market.

  • ABBIE is a gene-editing platform that can deliver genetic payloads using non-viral vectors. It uses targeted integration to insert larger DNA sequences into target cells' genomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.